SynuSight Biotech is committed to pioneering transformative diagnostic and therapeutic molecules for neurodegenerative diseases through cutting-edge scientific expertise and innovative technology platforms, ultimately benefiting millions of patients worldwide.
Explore
SynuSight team specializes in studying the misfolding and pathological aggregation of proteins such as α-Syn, tau, and Aβ. By integrating cutting-edge technologies like Cryo-EM electron diffraction, Helical filament imaging, and In-cell NMR spectroscopy, we have built unparalleled expertise in key neurodegenerative disease targets, unlocking new possibilities for innovative therapeutic molecule development.
ExploreSynuSight has developed 18F-FD4, a novel small-molecule tracer with a unique core structure, through its structure-driven drug discovery platform combining systematic studies of ligand-α-Syn interactions with advanced AI and CADD approaches. Early investigator-initiated trials (IIT) have demonstrated its excellent blood-brain barrier penetration and superior imaging performance in both Parkinson's disease (PD) and multiple system atrophy (MSA) patients.
Explore
Our Value